Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ Suzetrigine, sold as twice-daily Journavx, a non-addictive prescription drug for ...
The Mass Spectrometry market valued at US$ 5.82 Billion in 2023, is forecasted to grow at a robust CAGR of 7.2%, reaching US$ 6.33 Billion in 2024 and an impressive US$ 9.62 Billion by 2030. The ...